Market Pulse of the Healthcare Sector - Anthera Pharmaceuticals, Flexion Therapeutics, AcelRx Pharmaceuticals, Discovery Laboratories and Cara Therapeutics
NEW YORK, September 28, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following equities: Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), Flexion Therapeutics, Inc. (NASDAQ: FLXN), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Discovery Laboratories, Inc. (NASDAQ: DSCO), and Cara Therapeutics, Inc. (NASDAQ: CARA). On Friday, September 25, 2015, Nasdaq ended at 4,686.50, down 1.01%, Dow Jones advanced 0.70% to finish the day at 16,314.67, and the S&P closed at 1,931.34, down 0.05%. Register for your complimentary reports at the links given below.
--
Anthera Pharmaceuticals Inc.
--
Anthera Pharmaceuticals Inc.'s stock edged lower by 10.79% to close Friday's session at USD 7.52. The company's shares oscillated between USD 7.35 and USD 8.60. The stock recorded a trading volume of 0.85 million shares, which was below its 50-day daily average volume of 1.08 million shares. Over the last three days Anthera Pharmaceuticals Inc.'s shares have declined by 15.32% and in the past one week the stock has moved down 21.67%. Furthermore, over the last three months the stock has lost 8.96% and in the past six months the shares have picked up 74.07%. The stock is trading at a price to book ratio of 10.02. Additionally, the stock is trading at price to sales ratio of 559.13. Sign up and read the free notes on ANTH at: http://www.aciassociation.com/ANTH.pdf
--
Flexion Therapeutics Inc.
--
The stock of Flexion Therapeutics Inc. lost 18.69% to close Friday's session at USD 19.01. The shares of the company moved in the range of USD 18.47 and USD 23.18 in trade during the day. A trading volume of 0.85 million shares was recorded, which was greater than its 150-day daily average volume of 0.16 million shares and above its 52-week average volume of 0.13 million shares. Over the last five days Flexion Therapeutics Inc.'s shares have declined by 23.93% and in the past one month the stock has lost 16.48%. Additionally, over the last three months the stock has declined 11.99% and in the past six months the shares have registered a loss of 15.06%. Register for free on ACI Association and access the latest research on FLXN at: http://www.aciassociation.com/FLXN.pdf
--
AcelRx Pharmaceuticals Inc.
--
AcelRx Pharmaceuticals Inc.'s stock decreased by 10.53% to close Friday's session at USD 3.40. The company's shares fluctuated in the range of USD 3.30 and USD 3.85. A total of 0.83 million shares exchanged hands, which surpassed its 50-day daily average volume of 0.56 million shares. Over the last three days AcelRx Pharmaceuticals Inc.'s shares have declined by 12.82% and in the past one week the stock has moved down 14.36%. Furthermore, over the last three months the stock has lost 16.05% and in the past six months the shares have shed 9.09%. The stock is trading at a price to book ratio of 4.52 which compares to a historical PB ratio close to 6.31. Additionally, the stock is trading at a price to sales ratio of 21.08. The complete research on ACRX is available for free at: http://www.aciassociation.com/ACRX.pdf
--
Discovery Laboratories Inc.
--
Discovery Laboratories Inc.'s stock slipped by 1.53% to close Friday's session at USD 0.34. The company's shares oscillated between USD 0.31 and USD 0.39 marking a new 52-week low during the session. The stock recorded a trading volume of 0.81 million shares, which was above its 50-day daily average volume of 0.41 million shares. Over the last five days Discovery Laboratories Inc.'s shares have declined by 24.44% and in the past one month the stock has lost 12.82%. In addition, over the last three months the stock has lost 50.00% and year to date the shares have shed 70.69%. The company has returned 12.82% in the past one month and 80.35% in the past one year, on a compounded total return basis. Free in-depth research on DSCO is available at: http://www.aciassociation.com/DSCO.pdf
--
Cara Therapeutics Inc.
--
Cara Therapeutics Inc.'s stock declined 19.37% to close Friday's session at USD 16.15. The share price vacillated between USD 15.80 and USD 20.32 in trade during the day. The stock recorded a trading volume of 0.79 million shares, which was above its 50-day daily average volume of 0.50 million shares. Over the last three days Cara Therapeutics Inc.'s shares have declined by 19.25% and in the past one week the stock has moved down 25.54%. Moreover, in the last six months the stock has gained 59.43% and year to date the shares have picked up 61.99%. The complimentary notes on CARA can be downloaded in PDF format at: http://www.aciassociation.com/CARA.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE www.aciassociation.com
Share this article